<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03537937</url>
  </required_header>
  <id_info>
    <org_study_id>171272</org_study_id>
    <nct_id>NCT03537937</nct_id>
  </id_info>
  <brief_title>Pragmatic Investigation of optimaL Oxygen Targets Trial</brief_title>
  <acronym>PILOT</acronym>
  <official_title>Pragmatic Investigation of optimaL Oxygen Targets (PILOT) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mechanical ventilation of ICU patients universally involves titration of the fraction of&#xD;
      inspired oxygen (FiO2) to maintain arterial oxygen saturation (SpO2). Despite decades of ICU&#xD;
      practice, however, the optimal SpO2 target remains unknown. Current guidelines offer&#xD;
      divergent recommendations as to the optimal SpO2 target. Therefore, we propose a&#xD;
      2,250-patient cluster-randomized cluster-crossover trial comparing a lower SpO2 target (90%;&#xD;
      range 88-92%), an intermediate SpO2 target (94%; range 92-96%), and a higher SpO2 target&#xD;
      (98%; range 96-100%) with regard to the outcome of days alive and free of invasive mechanical&#xD;
      ventilation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>In the PILOT trial, the entire study ICU will be assigned to a single SpO2 target (cluster-randomized) and the ICU will switch between lower, intermediate, and higher SpO2 targets every two months in a randomly generated sequence (cluster-crossover).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Observer bias will be minimized by use of objective endpoints collected in duplicate by [1] study personnel blinded to group assignment and [2] automated data extraction from the electronic health record.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free days (VFDs) to study day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days alive and free from invasive mechanical ventilation between the final liberation from invasive mechanical ventilation before 28 days and study day 28. Patients who continue to receive invasive mechanical ventilation at day 28 or have died prior to day 28 will receive zero VFDs. For patients who return to invasive mechanical ventilation and are subsequently liberated from invasive mechanical ventilation prior to day 28, VFDs will be counted from final liberation from mechanical ventilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day, in-hospital Mortality (Secondary Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>All-cause mortality prior to discharge from the hospital, assessed at 28 days after enrollment (Secondary Outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Mortality (Exploratory Clinical Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>All-cause mortality prior to transfer out of the intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasopressor-free days (Exploratory Clinical Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days alive and free from vasopressor receipt between the final receipt of vasopressors before 28 days and study day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy-free days (Exploratory Clinical Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days alive and free from renal replacement therapy between the final receipt of renal replacement therapy before 28 days and study day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care unit-free days (Exploratory Clinical Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days alive and free from intensive care unit admission after the final transfer out of the intensive care unit before 28 days to study day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days (Exploratory Clinical Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days alive and free from hospital admission to study day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily non-respiratory Sequential Organ Failure Assessment (SOFA) Score (Exploratory Organ Function Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>The Sequential Organ Failure Assessment (SOFA) score (Vincent et al Critical Care Medicine 1998) is composed of scores from six organ systems, graded from 0 to 4 according to the degree of dysfunction or failure. Scores range from 0 (no evidence of organ dysfunction or failure) to 24 (evidence of severe dysfunction failure in each of the six organ systems). The modified non-respiratory SOFA score is composed of scores from five of the six organ systems included in the complete SOFA score (excluding the respiratory system), graded on the same scale as the complete SOFA score. Scores range from 0 (no evidence of organ dysfunction or failure) to 20 (evidence of severe organ dysfunction or failure in each of the five organ systems assessed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma creatinine (Exploratory Organ Function Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Daily plasma creatinine value (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma lactate (Exploratory Organ Function Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Daily plasma lactate value (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute respiratory distress syndrome (ARDS) (Exploratory Organ Function Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Presence of ARDS by Berlin Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury (AKI) (Exploratory Organ Function Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Presence of Stage II or greater AKI by Kidney Disease: Improving Global Outcomes (KDIGO) criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Atrial arrhythmia (Exploratory Safety Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Documented atrial arrhythmia</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventricular arrhythmia (Exploratory Safety Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Documented ventricular arrhythmia</description>
  </other_outcome>
  <other_outcome>
    <measure>Cardiac arrest (Exploratory Safety Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Cardiac arrest with return of spontaneous circulation</description>
  </other_outcome>
  <other_outcome>
    <measure>Pneumothorax or pneumomediastinum (Exploratory Safety Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>Pneumothorax or pneumomediastinum as defined by documentation in the electronic health record by treating clinicians or radiology of a pneumothorax on thoracic imaging or thoracic ultrasound.</description>
  </other_outcome>
  <other_outcome>
    <measure>Ischemic stroke (Exploratory Safety Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>New ischemic stroke between enrollment and 28 days after enrollment as diagnosed by computed tomography, magnetic resonance imaging, or cerebral angiography.</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction (Exploratory Safety Outcome)</measure>
    <time_frame>28 days</time_frame>
    <description>New myocardial infarction between enrollment and 28 days after enrollment, defined as detection of a rise in cardiac troponin values with at least one value above the 99th percentile and clinical evidence of acute myocardial ischemia.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2541</enrollment>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Lower SpO2 Target</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 90% (range 88-92%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate SpO2 Target</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 94% (range 92-96%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Higher SpO2 Target</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During invasive mechanical ventilation in a study location, the fraction of inspired oxygen will be titrated to target an arterial oxygen saturation of 98% (range 96-100%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lower SpO2 Target</intervention_name>
    <description>SpO2 target 90% (range 88-92%)</description>
    <arm_group_label>Lower SpO2 Target</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intermediate SpO2 Target</intervention_name>
    <description>SpO2 target 94% (range 92-96%)</description>
    <arm_group_label>Intermediate SpO2 Target</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Higher SpO2 Target</intervention_name>
    <description>SpO2 target 98% (range 96-100%)</description>
    <arm_group_label>Higher SpO2 Target</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years&#xD;
&#xD;
          2. Receiving mechanical ventilation through an endotracheal tube or tracheostomy&#xD;
&#xD;
          3. Admitted to the study ICU or admission to the study ICU from the emergency department&#xD;
             is planned&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known pregnancy or beta hCG level greater than the laboratory upper limit of normal in&#xD;
             a patient capable of becoming pregnant&#xD;
&#xD;
          2. Known to be a prisoner&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew W Semler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2018</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Matthew Semler</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The NIH's guidelines for data sharing will serve as the model for the approach we will follow for the proposed investigation;&#xD;
http://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm&#xD;
Even though the final dataset will be stripped of identifiers prior to release for sharing, the inherent link between the period in which the patient was admitted to the study ICU and group assignment in a cluster-crossover trial introduces a significant risk for deductive disclosure of subjects. Thus, we will make the data and associated documentation available to users only under a data sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

